Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXR NASDAQ:EMBC NASDAQ:KRMD NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.82-0.6%$10.21$8.08▼$14.76$49.51M0.299,498 shs1,081 shsEMBCEmbecta$3.32-0.5%$6.99$2.77▼$15.55$196.68M1.091.40 million shs560,081 shsKRMDKORU Medical Systems$4.12-1.4%$4.17$2.68▼$6.61$189.23M0.43167,514 shs14,213 shsTLSITriSalus Life Sciences$3.37+2.9%$3.99$2.20▼$7.95$206.68M0.56283,738 shs174,913 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor-2.42%-6.56%-15.06%-14.84%+25.47%EMBCEmbecta+1.22%+0.30%-63.12%-67.54%-68.44%KRMDKORU Medical Systems+0.72%+0.97%+2.45%-12.37%+42.66%TLSITriSalus Life Sciences+2.51%-5.22%-27.17%-35.38%-41.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.82-0.6%$10.21$8.08▼$14.76$49.51M0.299,498 shs1,081 shsEMBCEmbecta$3.32-0.5%$6.99$2.77▼$15.55$196.68M1.091.40 million shs560,081 shsKRMDKORU Medical Systems$4.12-1.4%$4.17$2.68▼$6.61$189.23M0.43167,514 shs14,213 shsTLSITriSalus Life Sciences$3.37+2.9%$3.99$2.20▼$7.95$206.68M0.56283,738 shs174,913 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor-2.42%-6.56%-15.06%-14.84%+25.47%EMBCEmbecta+1.22%+0.30%-63.12%-67.54%-68.44%KRMDKORU Medical Systems+0.72%+0.97%+2.45%-12.37%+42.66%TLSITriSalus Life Sciences+2.51%-5.22%-27.17%-35.38%-41.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 2.50Moderate BuyN/AN/AEMBCEmbecta 1.40Strong Sell$11.00231.83% UpsideKRMDKORU Medical Systems 2.60Moderate Buy$7.2575.97% UpsideTLSITriSalus Life Sciences 2.25Hold$7.50122.88% UpsideCurrent Analyst Ratings BreakdownLatest DXR, TLSI, EMBC, and KRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026EMBCEmbecta Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetUnderperform$11.00 ➝ $3.005/13/2026TLSITriSalus Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026TLSITriSalus Life Sciences Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.005/8/2026EMBCEmbecta Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/6/2026EMBCEmbecta Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/6/2026EMBCEmbecta MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$12.00 ➝ $5.005/5/2026EMBCEmbecta BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/21/2026KRMDKORU Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026EMBCEmbecta MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$14.00 ➝ $12.004/10/2026TLSITriSalus Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026DXRDaxor Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/AEMBCEmbecta$1.08B0.18$4.04 per share0.82($10.55) per share-0.31KRMDKORU Medical Systems$41.13M4.60N/AN/A$0.37 per share11.14TLSITriSalus Life Sciences$45.15M4.58N/AN/A$0.21 per share16.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/AN/AEMBCEmbecta$95.40M$1.901.741.89N/A10.73%-23.96%14.12%8/6/2026 (Estimated)KRMDKORU Medical Systems-$2.64M-$0.05N/A82.40N/A-5.27%-13.61%-8.33%8/5/2026 (Estimated)TLSITriSalus Life Sciences-$39.23M-$1.41N/AN/AN/A-60.85%N/A-69.91%8/11/2026 (Estimated)Latest DXR, TLSI, EMBC, and KRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q2 2026EMBCEmbecta$0.42$0.27-$0.15-$0.07$235.67 million$221.80 million3/12/2026Q4 2025KRMDKORU Medical Systems-$0.02-$0.01+$0.01-$0.01$10.90 million$10.90 million3/5/2026Q4 2025TLSITriSalus Life Sciences-$0.13-$0.12+$0.01-$0.21$13.20 million$13.21 million3/2/2026Q2 2025DXRDaxorN/A-$0.1010N/A-$0.1010N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/AEMBCEmbecta$0.6018.10%N/A31.58%N/AKRMDKORU Medical SystemsN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ALatest DXR, TLSI, EMBC, and KRMD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/1/2026EMBCEmbectaquarterly$0.011.2%5/28/20265/28/20266/15/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AEMBCEmbectaN/A2.461.68KRMDKORU Medical SystemsN/A2.331.82TLSITriSalus Life Sciences2.585.785.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%EMBCEmbecta93.83%KRMDKORU Medical Systems58.60%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%EMBCEmbecta1.30%KRMDKORU Medical Systems18.50%TLSITriSalus Life Sciences16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor375.04 million2.04 millionNot OptionableEMBCEmbecta1,85059.33 million58.56 millionOptionableKRMDKORU Medical Systems8045.93 million37.44 millionOptionableTLSITriSalus Life Sciences10661.42 million51.41 millionNot OptionableDXR, TLSI, EMBC, and KRMD HeadlinesRecent News About These CompaniesTLSI ALERT: Levi & Korsinsky Investigates TriSalus Life Sciences, Inc. on Behalf of Shareholders Who Lost MoneyMay 24, 2026 | newsfilecorp.comNTLSI (TLSI) Securities Fraud Investigation - Levi & KorsinskyMay 22, 2026 | prnewswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...May 20, 2026 | tmcnet.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmMay 20, 2026 | businesswire.comTriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationMay 20, 2026 | businesswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMay 19, 2026 | tmcnet.comLost Money on TriSalus Life Sciences, Inc. (TLSI)? Possible Fraud - Contact Levi & Korsinsky TodayMay 19, 2026 | newsfilecorp.comNTLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities FraudMay 19, 2026 | businesswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMay 19, 2026 | businesswire.comTriSalus Life Sciences (NASDAQ:TLSI) Director Purchases $24,600.00 in StockMay 19, 2026 | insidertrades.comLost Money on TriSalus Life Sciences, Inc. (TLSI)? Contact Levi & Korsinsky to Protect Your RightsMay 14, 2026 | newsfilecorp.comNTriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goalMay 14, 2026 | seekingalpha.comTriSalus Life Sciences Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2026 | zacks.comEarnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q1 2026 ResultMay 11, 2026 | finance.yahoo.comTriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical TrialMay 10, 2026 | uk.finance.yahoo.comLake Street Remains a Buy on TriSalus Life Sciences (TLSI)May 7, 2026 | theglobeandmail.comTriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comTriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver TumorsMay 4, 2026 | businesswire.comTriSalus Life Sciences Announces Planned Clinical Leadership TransitionApril 29, 2026 | tipranks.comTriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference CallApril 28, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXR, TLSI, EMBC, and KRMD Company DescriptionsDaxor NASDAQ:DXR$9.82 -0.06 (-0.57%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Embecta NASDAQ:EMBC$3.32 -0.02 (-0.45%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.KORU Medical Systems NASDAQ:KRMD$4.12 -0.06 (-1.48%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.TriSalus Life Sciences NASDAQ:TLSI$3.36 +0.10 (+2.91%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Keeps Winning After Family Dollar Divorce Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Meta's Manus Mess: Why China Blocked the Deal and What It Means Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
